Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

RBC Capital initiated coverage of Ocular Therapeutix (OCUL) with an Outperform rating and $17 price target Checks with key opinion leaders ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of pharmacologic therapy, including intravitreal injections of anti-VEGF ...

Global Bispecific Antibodies market size to surpass US$ 50 Billion By 2030 Says Kuick Research Delhi, March 17, 2025 (GLOBE ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...